Indaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit
Dr. Newman also to give two presentations on the Company’s Decoy platform at the event to be held in Boston...
Cancer
Elicio Therapeutics to Present Interim Data from the Ongoing Phase 1 Study of Investigational Therapeutic Cancer Vaccine, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at ASCO
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for...
The Canadian Dermatology Association launches its month-long National Sun Awareness Campaign, and its partnership and support of Melanoma Canada’s Mole Mobile Skin Cancer Screening Unit
OTTAWA, May 01, 2023 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) launches its month-long Sun Awareness Month campaign, urging...
IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors
Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group,...
Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma
ERAS-801 has demonstrated broad preclinical activity against oncogenic EGFR variants and wildtype alterations Initial THUNDERBBOLT-1 Phase 1 data in patients...
iCAD to Report First Quarter 2023 Financial Results on May 15, 2023
NASHUA, N.H., May 01, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer...
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
Media Release Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology (IO) combination of eftilagimod alpha...
Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities
CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on...
Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™
Structured To Extend Marker’s Financial Runway Through Year-End 2025 Marker Announces Leadership Transition & Provides Update on Operational Strategy HOUSTON,...
Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension
NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Predicine to Introduce PredicineALERT™ MRD Assay and Present Two ctDNA Studies in Genitourinary Cancers at AUA 2023 Annual Meeting
HAYWARD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announced today that it will present...
Preliminary Results for the Year Ended 31 December 2022
28 April 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the...
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that...
Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia
In patients with relapsed refractory acute myeloid leukemia (R/R AML) treated with a four-dose regimen consisting of 1.8 billion CYNK-001...
Lisata Therapeutics Announces Participation in Upcoming Conferences in May
BASKING RIDGE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced...
MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
Tavros Therapeutics and OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery
Multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s screening platform Partnership streamlines drug development for novel cancer...
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX:...
Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
Results published in peer-reviewed Cancer Research share novel insights into Chi3L1’s role in modulating Glioma stem cells and reinforces the...